Form 4: Arteris VP Sells Shares After Option Exercise

Arteris Inc.'s VP and General Counsel, Paul L. Alpern, exercised options and subsequently sold 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Paul L. Alpern, VP and General Counsel of Arteris, Inc. (AIP), reported transactions on December 4, 2025.
• Alpern exercised options to acquire 7,500 shares of Common Stock at an exercise price of $9.28 per share.
• Concurrently, Alpern sold 7,500 shares of Common Stock at a weighted average sale price of $16.0852 per share, with individual sales ranging from $16.00 to $16.20.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Alpern on June 5, 2025.
• Following these transactions, Alpern directly beneficially owns 65,277 shares of Arteris, Inc. Common Stock.
• The options exercised were part of a grant where 2,500 shares vest quarterly over 16 quarters, with vesting starting on April 1, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (option exercise and sale) which is common for executives managing their equity compensation. It does not indicate any significant positive or negative operational or financial news for the company.

Positives

• The executive realized a profit from exercising options and selling shares, indicating personal financial benefit.
• The transaction was pre-planned under a 10b5-1 plan, suggesting a systematic approach to managing equity rather than a reaction to new, undisclosed information.

Negatives

• The sale of shares by an executive could be interpreted by some investors as a lack of confidence, although it is a common practice for executives to diversify holdings or cover tax obligations.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

This filing is a routine insider transaction report and does not provide information to analyze broader industry trends or competitor actions.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a routine insider sale. Could be viewed as a slight negative by some due to executive selling, but offset by the 10b5-1 plan.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Continued vesting of remaining options (2,500 shares quarterly over 16 quarters, starting April 1, 2025).

Key Dates

Keywords

Arteris Inc., AIP, Paul L. Alpern, Form 4, insider trading, stock options, 10b5-1 plan, common stock, executive compensation, share sale